Loading stock data…
ONCY
$0.88+0.01 (+1.35%)
Market OpenUpdated 2:10 PM EDT
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oncolytics Biotech Inc. in the Healthcare sector is trading at $0.88. Wall Street consensus targets $4.12 (5 analysts), implying a +366.7% move over the next 12 months. The stock is currently 42% below its 52-week high of $1.51, remaining 15.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +366.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$0.88
Potential Downside
0%
Whystock Fair Value$0.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$4.12+366.7%
Range$2.95 – $6.08
Fundamentals
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$103.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
755.53%
Volume
Today's trading volume
641,695
Recent News
Oncolytics Biotech Reports Data in Colorectal Cancer Study
By Karen Roman Oncolytics Biotech Inc. (Nasdaq: ONCY) said it has new data showing the use of pelareorep in metastatic colorectal cancer has a 19.5-month median duration of response compared to […]
Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off
Oncolytics Biotech (NasdaqCM:ONCY) has completed its transition of incorporation from Alberta, Canada to Nevada, United States. The company has shifted its corporate headquarters to the U.S., with the move now formally in effect. Management has highlighted goals of greater operational efficiency and improved access to U.S. capital markets following the relocation. Oncolytics Biotech focuses on developing cancer therapeutics, and this jurisdiction change comes at a time when access to...
Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep
FDA decision puts pelareorep in focus Oncolytics Biotech (NasdaqCM:ONCY) is back on investor radars after the FDA granted Fast Track Designation to pelareorep in a combination regimen for second line KRAS mutant metastatic colorectal cancer. See our latest analysis for Oncolytics Biotech. The FDA Fast Track decision comes after a strong short term run, with a 1 day share price return of 26.99% and 7 day share price return of 22.78%, set against a 38.16% 1 year total shareholder return but...
Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer
Earlier in February 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, microsatellite-stable metastatic colorectal cancer, supported by clinical data showing improved outcomes versus standard care. This designation sharpens the company’s focus on gastrointestinal cancers, targeting a difficult-to-treat subgroup with an estimated multibillion-dollar annual addressable...
Oncolytics receives FDA Fast Track Designation for pelareorep
Oncolytics (ONCY) Biotech announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of patients with KRAS mutant, microsatellite-stable metastatic colorectal cancer in the second-line setting. As part of the Company’s increased focus on gastrointestinal cancer and analysis of the existing colorectal data set in the fall, the Company applied for and has now receiv